Syndax Pharmaceuticals (SNDX) Leerink Global Healthcare Conference 2026 summary

Commercial performance and product launches

• Two products launched: Revuforj for AML/ALL and Niktimvo for chronic GVHD, both showing strong initial uptake and revenue growth in their first year.

• Revuforj achieved $125M in first-year sales, with Q4 revenue of $44.2M and 38% quarter-over-quarter growth.

• Niktimvo generated $152M in 11 months, with Q4 revenue of $56M and 22% sequential growth.

• Both drugs are expanding into broader indications and patient populations, with significant momentum expected into 2026.

• Duration of therapy for Revuforj is expected to increase from 4–6 months to 6–12 months as maintenance use grows.

Market expansion and clinical strategy

• Revuforj is penetrating KMT2A and NPM1 markets, with NPM1 now accounting for 30%+ of new patients and expected to grow further.

• Niktimvo has penetrated 20% of the third-line GVHD market and is expected to expand with upcoming combination data in 2027–2028.

• Frontline AML market is estimated at $5–$7B, with pivotal studies (REVEAL and EVOLVE-2) underway to expand into this segment.

• Revuforj has demonstrated strong combinability with standard therapies, supporting its use in frontline and combination regimens.

• Additional studies are ongoing in myelofibrosis and IPF, with key data readouts expected in the near term.

Physician education and scientific engagement

• Extensive physician education initiatives are underway, including collaborations with advocacy groups and a strong presence at major congresses (ASH, ASCO, EHA).

• Over 24 presentations at ASH, with plans for significant data updates at upcoming meetings.

• Focus on educating clinicians about patient selection, management post-transplant, and combination therapy data.

• Real-world data and updates from ongoing studies will be shared at key medical meetings throughout the year.